WO2010115118A3 - Methods for preparing and using multichaperone-antigen complexes - Google Patents

Methods for preparing and using multichaperone-antigen complexes Download PDF

Info

Publication number
WO2010115118A3
WO2010115118A3 PCT/US2010/029803 US2010029803W WO2010115118A3 WO 2010115118 A3 WO2010115118 A3 WO 2010115118A3 US 2010029803 W US2010029803 W US 2010029803W WO 2010115118 A3 WO2010115118 A3 WO 2010115118A3
Authority
WO
WIPO (PCT)
Prior art keywords
multichaperone
methods
preparing
antigen complexes
complexes
Prior art date
Application number
PCT/US2010/029803
Other languages
French (fr)
Other versions
WO2010115118A2 (en
Inventor
Kenneth P. Leclair
Andrew J. Tomlinson
Original Assignee
Agenus Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc. filed Critical Agenus Inc.
Priority to EP10712860.5A priority Critical patent/EP2413953B1/en
Priority to CA2757524A priority patent/CA2757524A1/en
Priority to RU2011144575/10A priority patent/RU2011144575A/en
Priority to AU2010232490A priority patent/AU2010232490B2/en
Priority to US13/262,288 priority patent/US20120100173A1/en
Publication of WO2010115118A2 publication Critical patent/WO2010115118A2/en
Publication of WO2010115118A3 publication Critical patent/WO2010115118A3/en
Priority to US14/616,554 priority patent/US20150307567A1/en
Priority to US15/866,249 priority patent/US20180371034A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to methods for preparing and using multichaperone-antigen complexes. The present invention uses HOP affinity molecules in affinity methods to isolate multichaperone (multi-HSP)-antigen complexes. Such complexes have use in therapy.
PCT/US2010/029803 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes WO2010115118A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP10712860.5A EP2413953B1 (en) 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes
CA2757524A CA2757524A1 (en) 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes
RU2011144575/10A RU2011144575A (en) 2009-04-03 2010-04-02 METHODS FOR PRODUCING AND USING MULTI-CHAPERON-ANTIGENIC COMPLEXES
AU2010232490A AU2010232490B2 (en) 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes
US13/262,288 US20120100173A1 (en) 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes
US14/616,554 US20150307567A1 (en) 2009-04-03 2015-02-06 Methods for preparing and using multichaperone-antigen complexes
US15/866,249 US20180371034A1 (en) 2009-04-03 2018-01-09 Methods for preparing and using multichaperone-antigen complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21185009P 2009-04-03 2009-04-03
US61/211,850 2009-04-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/262,288 A-371-Of-International US20120100173A1 (en) 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes
US14/616,554 Continuation US20150307567A1 (en) 2009-04-03 2015-02-06 Methods for preparing and using multichaperone-antigen complexes

Publications (2)

Publication Number Publication Date
WO2010115118A2 WO2010115118A2 (en) 2010-10-07
WO2010115118A3 true WO2010115118A3 (en) 2011-08-25

Family

ID=42358392

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/029803 WO2010115118A2 (en) 2009-04-03 2010-04-02 Methods for preparing and using multichaperone-antigen complexes

Country Status (6)

Country Link
US (3) US20120100173A1 (en)
EP (1) EP2413953B1 (en)
AU (1) AU2010232490B2 (en)
CA (1) CA2757524A1 (en)
RU (2) RU2011144575A (en)
WO (1) WO2010115118A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
US9145449B2 (en) * 2013-02-04 2015-09-29 Chang Gung Memorial Hospital, Linkou Branch STIP1 polypeptides and uses thereof
AU2016215175B2 (en) * 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
CA2984643A1 (en) 2015-05-13 2016-11-17 Agenus Inc. Vaccines for treatment and prevention of cancer
JP7114477B2 (en) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド Identification, production and use of neoantigens
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
AU2018373154A1 (en) 2017-11-22 2020-07-02 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN110508029B (en) * 2019-09-04 2022-01-28 武玉香 Immunoaffinity column for simultaneously extracting florfenicol, chloramphenicol and thiamphenicol
CN112327883B (en) * 2020-11-27 2023-01-03 哈尔滨工程大学 Under-actuated surface vessel path tracking control method based on extended state observer
WO2023122327A2 (en) * 2021-12-24 2023-06-29 Avitide LLC Chi domain affinity ligands and agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2002028407A1 (en) * 2000-09-29 2002-04-11 University Of Connecticut Health Center Methods of recovering heat shock proteins and complexes thereof
WO2004035602A2 (en) * 2002-05-02 2004-04-29 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
CN1640887A (en) * 2004-01-08 2005-07-20 北京中天康泰生物科技有限公司 'Heat shock protein special extraction kit' for biological therapy
CN101297966A (en) * 2008-06-16 2008-11-05 黄常新 Tumor vaccine for intestinal cancer containing rich chaperone-antigenic peptide complexes and preparation thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137819A (en) 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
US5306307A (en) 1991-07-22 1994-04-26 Calcitek, Inc. Spinal disk implant
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5496934A (en) 1993-04-14 1996-03-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acids encoding a cellulose binding domain
ES2171454T3 (en) 1993-06-04 2002-09-16 Whitehead Biomedical Inst STRESS PROTEINS AND ITS USES.
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (en) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2231998A1 (en) 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
ES2439014T3 (en) 1998-02-20 2014-01-21 The University Of Miami Complex of antigenic peptide-modified heat shock protein
DE69935507T2 (en) 1998-04-03 2007-12-06 University Of Iowa Research Foundation METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM BY IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINES
SI1077722T1 (en) 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
UA77152C2 (en) 1999-09-25 2006-11-15 Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
JP2003527352A (en) 2000-01-13 2003-09-16 アンティジェニクス インコーポレーテッド Innate immune stimulating compounds of CPG and saponin and methods thereof
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2002028407A1 (en) * 2000-09-29 2002-04-11 University Of Connecticut Health Center Methods of recovering heat shock proteins and complexes thereof
WO2004035602A2 (en) * 2002-05-02 2004-04-29 University Of Connecticut Health Center Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
CN1640887A (en) * 2004-01-08 2005-07-20 北京中天康泰生物科技有限公司 'Heat shock protein special extraction kit' for biological therapy
CN101297966A (en) * 2008-06-16 2008-11-05 黄常新 Tumor vaccine for intestinal cancer containing rich chaperone-antigenic peptide complexes and preparation thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ARNOLD-SCHILD DANIELE ET AL: "One-step single-chain Fv recombinant antibody-based purification of gp96 for vaccine development", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 60, no. 15, 1 August 2000 (2000-08-01), pages 4175 - 4178, XP002175252, ISSN: 0008-5472 *
CARRIGAN PATRICIA E ET AL: "Domain : domain interactions within Hop, the Hsp70/Hsp90 organizing protein, are required for protein stability and structure", PROTEIN SCIENCE, vol. 15, no. 3, March 2006 (2006-03-01), pages 522 - 532, XP002639945, ISSN: 0961-8368 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; May 2009 (2009-05-01), ZHAO JIAN-GANG ET AL: "[Preparation of anticolon carcinoma vaccine with rich chaperone peptides and study on its anticancer efficacy].", XP002639948, Database accession no. NLM19434541 *
GONG JIANLIN ET AL: "A Heat Shock Protein 70-Based Vaccine with Enhanced Immunogenicity for Clinical Use", JOURNAL OF IMMUNOLOGY, vol. 184, no. 1, January 2010 (2010-01-01), pages 488 - 496, XP002639947, ISSN: 0022-1767 *
GRANER M ET AL: "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH MAR 2000 LNKD- PUBMED:10741715, vol. 6, no. 3, March 2000 (2000-03-01), pages 909 - 915, XP002639946, ISSN: 1078-0432 *
KING FRANK W ET AL: "Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 20, no. 22, 15 November 2001 (2001-11-15), pages 6297 - 6305, XP002639944, ISSN: 0261-4189 *
YI ZENG ET AL: "Chaperone-rich cell lysates, immune activation and tumor vaccination", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 3, 1 March 2006 (2006-03-01), pages 329 - 338, XP019333212, ISSN: 1432-0851, DOI: DOI:10.1007/S00262-005-0694-1 *
ZHONGHUA WEI CHANG WAI KE ZA ZHI = CHINESE JOURNAL OF GASTROINTESTINAL SURGERY MAY 2009 LNKD- PUBMED:19434541, vol. 12, no. 3, May 2009 (2009-05-01), pages 290 - 293, ISSN: 1671-0274 *

Also Published As

Publication number Publication date
RU2015117604A3 (en) 2018-12-20
CA2757524A1 (en) 2010-10-07
WO2010115118A2 (en) 2010-10-07
EP2413953B1 (en) 2017-11-08
US20150307567A1 (en) 2015-10-29
US20120100173A1 (en) 2012-04-26
AU2010232490B2 (en) 2016-08-11
US20180371034A1 (en) 2018-12-27
RU2015117604A (en) 2015-10-27
RU2011144575A (en) 2013-05-10
EP2413953A2 (en) 2012-02-08
AU2010232490A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
WO2010115118A3 (en) Methods for preparing and using multichaperone-antigen complexes
ZA201005090B (en) Carbon aerogels, process for their preparation and their use
WO2008089397A3 (en) Adrb2 cancer markers
MX337838B (en) Bifidobacteria crispr sequences.
TN2010000213A1 (en) Wise binding antibodies and epitopes
IL211892A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
HK1163587A1 (en) Process, dispersions and use
IL211890A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
EP2133077A4 (en) Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase iv
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
ZA201001434B (en) 2-aza-bicyclo[3.3.0]octane derivatives
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
AP2011005657A0 (en) Carbon block filter.
WO2010078945A3 (en) Cancer treatment
EP2503995A4 (en) Lyophilization methods, compositions, and kits
IL211891A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
SG2013071303A (en) Methods for preparing composition, sheet comprising the composition and electrode comprising the sheet
WO2009150255A3 (en) Markers for predicting response and survival in anti-egfr treated patients
IL213048A0 (en) Novel ultra stable zeolite y and method for manufacturig the same
WO2010039502A3 (en) Micrornas in idiopathic pulmonary fibrosis
WO2011153431A3 (en) Peripheral blood sparc antibodies and uses thereof
PL2225314T3 (en) Silicone-self-adhesives, method for the production thereof, complexes using same and uses
GB0817998D0 (en) Process,dispersions and use
EP2576575A4 (en) Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10712860

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2757524

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010712860

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010712860

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011144575

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010232490

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010232490

Country of ref document: AU

Date of ref document: 20100402

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13262288

Country of ref document: US